



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/649,232	08/26/2003	Edward P. Ingenito	10991-002004	6203

23628 7590 02/28/2007
WOLF GREENFIELD & SACKS, PC
FEDERAL RESERVE PLAZA
600 ATLANTIC AVENUE
BOSTON, MA 02210-2206

EXAMINER

WILLIAMS, CATHERINE SERKE

ART UNIT	PAPER NUMBER
----------	--------------

3763

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	02/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/649,232

Applicant(s)

INGENITO, EDWARD P.

Examiner

Catherine S. Williams

Art Unit

3763

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02 November 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-18 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in-

(1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or

(2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a).

Claims 1 and 14-18 are rejected under 35 U.S.C. 102(e) as being anticipated by Perkins et al (6,287,290).

Perkins discloses methods, systems and kits for lung volume reduction that includes advancing a bronchoscope (see 8:18+) and introducing biological material to reduce the volume of the lung (see 10:37+). The method includes blocking air flow (9:19+). The collapsed region may be over inflated prior to collapsing the region (9:33). An oxygen rich gas can be introduced prior to collapse (see 6:59+ and 9:45). The collapsed region will be sealed by methods including using a plug of hydrated collagen hydrogel (biological material for promoting fibrosis and increasing surface tension), gluing (including fibrin see 2:39) and energy-mediated tissue adhesion, etc (10:37-45).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Perkins et al in view of Edwardson et al (US 5,739,288).

Perkins meets the claim limitations as described above but fails to disclose the use of fibrinogen and a fibrinogen activator such as thrombin.

Edwardson et al disclose a fibrin sealant composition that can be used for sealing tracheal and bronchial anastomoses and air leaks or lacerations of the lung (promoting fibrosis) that includes fibrinogen, thrombin, clot promoting factor XIIIa and antibiotics. Since the invention of Perkins is drawn to closing a region of the lung by gluing tissue (see Perkins 10:40) and Edwardson teaches a composition to enhance the closure of leaks or laceration of the lung (i.e. a tissue sealant) a combination is proper. At the time of the invention, it would have been obvious to use the fibrin sealant of Edwardson et al in order to provide an enhanced fibrin formulation for tissue closure thereby improving patient recovery time.

Claims 2-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Perkins in view of Edwardson in further view of Antanavich et al (US 5,814,022).

Perkins meets the claim limitations as described above but fails to disclose the use of fibrinogen and a fibrinogen activator such as thrombin.

Edwardson et al disclose a fibrin sealant composition that can be used for sealing tracheal and bronchial anastomoses and air leaks or lacerations of the lung (promoting fibrosis) that includes fibrinogen, thrombin, clot promoting factor XIIIa and antibiotics. Since the invention of Perkins is drawn to closing a region of the lung by gluing tissue (see Perkins 10:40) and Edwardson teaches a composition to enhance the closure of leaks or laceration of the lung (i.e. a tissue sealant) a combination is proper. At the time of the invention, it would have been obvious to use the fibrin sealant of Edwardson et al in order to provide an enhanced fibrin formulation for tissue closure thereby improving patient recovery time.

Perkins in view of Edwardson meets the claim limitations as described above but fails to include the composition comprising 3-12% fibrinogen.

Antanavich discloses a method and apparatus for applying tissue sealant that includes the use of an adhesive protein solution having a fibrinogen content of from 3 to 12% with clot promoting factor XIIIa and further notes that one reason for this arrangement is that the strength of the sealant is proportional to the fibrinogen concentration. Since the invention of Perkins is drawn to closing a region of the lung by gluing tissue (see Perkins 10:40) and Antanavich teaches an enhanced fibrin sealant composition a combination is proper. At the time of the invention, it would have been obvious to incorporate the concentration of fibrinogen as taught by Antanavich et al into the invention of Perkins in order to have an adhesive protein solution that is less prone to clogging before administered to the therapeutic site as taught by Antanavich et al.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-3,13 and 15 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 14,15,22,23,31,55,60 of copending Application No. 10/069307. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are a broader recitation of the copending claims.


This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine S. Williams whose telephone number is 571/2724970. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 571/27249773552. The fax phone numbers for the organization where this application or proceeding is assigned are (571) 273-8300 for regular communications and (571) 273-8300 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571/2722975.


Catherine S. Williams
February 20, 2007

CATHERINE S. WILLIAMS
PRIMARY EXAMINER